At Center For Sight, we offer a variety of intraocular lens (IOL) options based on your individual visual needs and goals. At your cataract consultation, we will review the best lens options with you to help you choose the right IOL for your desired visual outcome.
In February 2021, the FDA approved the TECNIS Eyhance™ Intraocular Lenses for the treatment of cataracts. The Eyhance lens is a next-generation intraocular lens. Built on the proven TECNIS® platform, TECNIS Eyhance combines low-light performance with breakthrough refractive surface design, providing a new kind of monofocal experience for cataract patients. Data has shown that the Eyhance lens has a low occurrence of halos and glare, making it a strong option for patients concerned about traditional monofocal lens side effects.
- The TECNIS Eyhance is also available in a Toric version for patients with astigmatism.
In July, 2016, The FDA approved the TECNIS Symfony® Intraocular Lenses for the treatment of cataracts. The TECNIS Symfony lens is the first and only intraocular lens (IOL) available in the United States that provides a full range of continuous high-quality vision following cataract surgery, while also alleviating the effects of presbyopia or astigmatism.
The IOL most commonly used in basic cataract surgery is a monofocal lens, which only allows a person to see distance without glasses. The Symfony lens was developed to improve both the range and quality of vision, allowing people to see clearly at all distances. The Symfony lens provides clear day and night vision, reducing the appearance of halos and glare around bright lights, while dramatically decreasing dependency on glasses at all distances.
- The TECNIS Symfony is also available in a Toric version for patients with astigmatism.
The TECNIS® Multifocal lens is capable of providing a dual range of high-quality vision tailored for each patient’s lifestyle. The lens offers sharp vision at distance and near. The TECNIS MultiFocal provides high contrast vision in most lighting scenarios, resulting in fewer low-light complications. Most patients immediately experience an excellent visual outcome with excellent distance and reading vision without glasses.
The PanOptix lens is clinically shown to deliver an exceptional combination of near, intermediate and distance vision while significantly reducing the need for glasses after cataract surgery. To date, the PanOptix has resulted in remarkable patient outcomes, with more than 99% of PanOptix patients in the FDA clinical study stating they would choose the same lens again.
A distinctive feature of the PanOptix IOL is that it has been specifically designed for today’s active lifestyles, offering clear vision when viewing mobile devices and computer screens, to high-quality distance vision in a range of lighting conditions.